一项评估利妥昔单抗联合苯达莫司汀一线治疗结外边缘区淋巴瘤的国际分析
该国际 consortium 分析纳入 237 例结外边缘区淋巴瘤患者,评估一线苯达莫司汀联合利妥昔单抗(BR)的安全性和疗效。总缓解率 93.2%,完全缓解率 81%,估计 5 年 PFS 80.5%、OS 89.6%。利妥昔单抗维持与更长 PFS 相关(HR=0.16,P=.016),但未影响 OS;BR 治疗期间 13% 发生感染并发症,带状疱疹最常见(4%)。
要点
- BR 一线治疗 EMZL 总缓解率 93.2%,完全缓解率 81%。
- 估计 5 年 PFS 80.5%(95%CI 73.1%-86%),OS 89.6%(95%CI 83.1%-93.6%)。
- 利妥昔单抗维持与更长 PFS 相关(HR=0.16,P=.016),未影响 OS。
核心结论
- BR 是 EMZL 高效的一线方案,可获得持久缓解并克服已知不良预后因素,但治疗与带状疱疹发生相关,因此可考虑预防性治疗。
研究设计与样本
- 国际 consortium 分析,纳入 237 例接受一线 BR 治疗的结外边缘区淋巴瘤患者,中位年龄 63 岁(范围 21-85 岁)。
主要发现
- 大多数患者 ECOG 体能状态 0-1(n=228;96.2%)、III/IV 期(n=179;75.5%)、MALT-IPI 中危(49.8%)或高危(33.3%)。
- 患者接受中位 6 个周期(范围 1-8)BR,20.3%(n=48)接受利妥昔单抗维持。
- BR 治疗期间 13% 发生感染并发症,带状疱疹(4%)最常见。
- 总缓解率 93.2%,完全缓解率 81%;估计 5 年 PFS 80.5%(95%CI 73.1%-86%),OS 89.6%(95%CI 83.1%-93.6%)。
- MALT-IPI 未能预测结局;多变量模型中,B 症状与更短 PFS 相关;利妥昔单抗维持与更长 PFS 相关(HR=0.16;95%CI 0.04-0.71;P=.016),但未影响 OS。
临床怎么用
- 作者认为 BR 是 EMZL 高效的一线方案,可获得持久缓解并克服已知不良预后因素。
- 作者认为该方案与带状疱疹发生相关,因此可考虑预防性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which bendamustine with rituximab (BR) is an established approach. We analyzed the safety and efficacy of frontline BR in EMZL using a large international consortium. We included 237 patients with a median age of 63 years (range, 21-85). Most patients presented with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (n = 228; 96.2%), stage III/IV (n = 179; 75.5%), and intermediate (49.8%) or high (33.3%) Mucosa Associated Lymphoid Tissue International Prognosis Index (MALT-IPI). Patients received a median of 6 (range, 1-8) cycles of BR, and 20.3% (n = 48) received rituximab maintenance. Thirteen percent experienced infectious complications during BR therapy; herpes zoster (4%) was the most common. Overall response rate was 93.2% with 81% complete responses. Estimated 5-year progression-free survival (PFS) and overall survival (OS) were 80.5% (95% CI, 73.1% to 86%) and 89.6% (95% CI, 83.1% to 93.6%), respectively. MALT-IPI failed to predict outcomes. In the multivariable model, the presence of B symptoms was associated with shorter PFS. Rituximab maintenance was associated with longer PFS (hazard ratio = 0.16; 95% CI, 0.04-0.71; P = .016) but did not impact OS. BR is a highly effective upfront regimen in EMZL, providing durable remissions and overcoming known adverse prognosis factors. This regimen is associated with occurrence of herpes zoster; thus, prophylactic treatment may be considered.
引用
- Alderuccio JP, Arcaini L, Watkins MP, et al. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022. PMID: 35196377. doi:10.1182/bloodadvances.2021006844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。